ImaRx Therapeutics, Inc. News
ImaRx Schedules Release of First Quarter 2008 Financial Results
The live webcast can be accessed through ImaRx's corporate website at www.imarx.com and will be archived on the website for 14 days following the event.
Interested parties may access the conference call by dialing (877) 407-4018 in the U.S. and
About ImaRx Therapeutics
ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. The Company's commercialization efforts are currently focused on its product, urokinase, for the treatment of acute massive pulmonary embolism.
Contacts: The Ruth Group (Investors/Media) Sara Ephraim/Jason Rando 646-536-7002 or 7025 sephraim@theruthgroup.com jrando@theruthgroup.com
SOURCE ImaRx Therapeutics, Inc.
Search Our News Using Google Search
Can't find what you want? Try using Google:
